Skin dendritic cells progressively subvert the activation of pathogenic type-2 immunity upon epicutaneous allergen immunotherapy

• Léo Laoubi,
• Hugh Sampson,
• Lucie Mondoulet,
• Jean-François Nicolas,
• Vincent Dioszeghy,
• Marc Vocanson

Affiliations

Léo Laoubi

CIRI – Centre International de Recherche en Infectiologie, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5308, Lyon, France; DBV Technologies, Montrouge, France

Hugh Sampson

DBV Technologies, Montrouge, France; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, United States

Lucie Mondoulet

DBV Technologies, Montrouge, France

Jean-François Nicolas

CIRI – Centre International de Recherche en Infectiologie, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5308, Lyon, France; Allergy and Clinical Immunology Department, Lyon Sud University Hospital, Pierre Bénite, France

Vincent Dioszeghy

DBV Technologies, Montrouge, France

Marc Vocanson

CIRI – Centre International de Recherche en Infectiologie, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5308, Lyon, France